Radical Cholecystectomy Guidelines for Gallbladder Cancer

Indications by Tumor Stage

Radical cholecystectomy (extended cholecystectomy with en‑bloc hepatic resection and regional lymphadenectomy, with or without bile‑duct excision) is indicated for gallbladder cancer stage T1b (muscle‑layer invasion) or higher【1】【2】【3】.
Simple cholecystectomy alone is sufficient for T1a disease when the gallbladder is removed intact with negative margins【1】【2】.
After complete staging—including diagnostic laparoscopy—radical re‑resection is strongly recommended for T1b and more advanced tumors【1】【2】【3】.
This recommendation applies both to cancers incidentally discovered on pathology and to those diagnosed pre‑operatively【1】【4】.
Complete surgical resection remains the only potentially curative treatment for gallbladder cancer【1】【3】.

Extended cholecystectomy entails removal of the gallbladder as the primary step【1】【2】【3】.
En‑bloc hepatic resection of the gallbladder bed with a ≥2 cm liver margin is performed; major hepatectomy (e.g., caudate lobectomy or extended right‑lobe resection) may be required for stage III–IV disease and has been linked to higher 5‑year survival rates【1】【3】.
Liver resection should be limited to cases where disease removal necessitates it, because it raises surgical complications without an independent survival advantage【4】 (NCCN).
Regional lymphadenectomy targets the porta hepatis, gastro‑hepatic ligament, and retroduodenal nodal stations【1】【4】 (NCCN).
Bile‑duct excision may be added when tumor involvement of the biliary tree is suspected【1】【2】【3】.
Nodal disease outside the regional stations (celiac, retropancreatic, interaortocaval) is considered unresectable【4】 (NCCN).

Mandatory staging before radical surgery includes a thorough history, physical examination, complete blood count, liver‑function tests, chest imaging (X‑ray or CT), and abdominal cross‑sectional imaging (CT or MRI)【1】【2】【3】【4】 (NCCN).
Diagnostic laparoscopy is strongly recommended prior to laparotomy to detect peritoneal or superficial liver metastases not visible on imaging【4】 (NCCN).
Endoscopic retrograde cholangiography or percutaneous trans‑hepatic cholangiography should be performed when biliary obstruction is suspected【1】【2】.
Endoscopic ultrasonography and cholangioscopy are appropriate adjuncts for detailed staging when indicated【1】【3】.

For incidental gallbladder cancer discovered intra‑operatively, immediate frozen‑section staging is advised【4】 (NCCN).
If resectability is confirmed, an extended cholecystectomy can be performed during the same operation, provided the surgeon has expertise in this complex procedure【1】【2】【4】 (NCCN).
Surgeons without specific training in radical cholecystectomy should not undertake the operation【4】 (NCCN).
When a T1b or higher lesion is identified on final pathology, radical re‑resection is indicated after confirming absence of metastatic disease with cross‑sectional imaging and laparoscopy【4】 (NCCN).
Approximately 74 % of patients who undergo re‑exploration after an incidental diagnosis have residual cancer found intra‑operatively【4】 (NCCN).

Fluoropyrimidine‑based chemoradiation is recommended for all resected gallbladder cancers except T1b, N0 disease【4】 (NCCN).
Fluorouracil‑based chemotherapy has demonstrated a survival benefit after non‑curative resections【1】.
Gemcitabine‑based chemotherapy is also an acceptable adjuvant option【4】 (NCCN).

Overall 5‑year survival for gallbladder cancer remains low, ranging from 5 % to 10 % despite aggressive surgical approaches【1】.

The American College of Surgeons recommends that complete surgical resection is the only potentially curative treatment for gallbladder tumors, with the extent of surgery determined by the tumor stage according to the TNM classification 5, 6
For T1a tumors (invasion of the lamina propria only), simple cholecystectomy is sufficient, and no additional resection is necessary if the gallbladder has been removed intact, with patients requiring only surveillance without additional intervention 5, 6, 7
For T1b tumors (invasion of the muscular layer), extended cholecystectomy with block resection of the liver and regional lymphadenectomy is strongly recommended, with the liver resection including the gallbladder bed with a 2 cm margin of liver tissue 5, 6, 8
The lymphadenectomy should target the lymph nodes along the cystic duct, common bile duct, hepatic artery, and portal vein 8

A complete preoperative evaluation is essential before any therapeutic decision, as 50% of patients present with lymph node involvement and 10-20% have peritoneal or distant metastases at the time of diagnosis, including chest radiography, abdominal CT scan (or abdominal MRI/CT scan if already performed), and laparoscopic exploration to detect peritoneal or superficial liver metastases not detected otherwise 9, 10, 7

The American Society of Clinical Oncology recommends that fluorouracil-based chemotherapy has been associated with a survival benefit after non-curative resection 5, 8
Postoperative chemoradiotherapy may be considered as an option, with local regional failure rates reaching 52% after surgical resection 5

The 5-year survival rates vary significantly according to the stage, with intrahepatic cholangiocarcinoma having a 5-year survival rate of up to 40%, hilar cholangiocarcinoma having a 5-year survival rate of 20%, and distal extrahepatic cholangiocarcinoma having a 5-year survival rate of 20-30% 9, 11, 7
The median survival for intrahepatic cholangiocarcinoma is 18-30 months without hilar involvement and 12-24 months with perihilar tumor 11, 7
Lymph node involvement is the most important negative prognostic factor, present in 50% of patients at diagnosis and associated with poor surgical outcomes 9, 10, 7